Age-Related Impaired Efficacy of Bone Marrow Cell Therapy for Myocardial Infarction Reflects a Decrease in B Lymphocytes

作者：An, Songtao; Wang, Xiaoyin; Ruck, Melissa A.; Rodriguez, Hilda J.; Kostyushev, Dmitry S.; Varga, Monika; Luu, Emmy; Derakhshandeh, Ronak; Suchkov, Sergey V.; Kogan, Scott C.; Hermiston, Michelle L.; Springer, Matthew L.^*

来源：Molecular Therapy, 2018, 26(7): 1685-1693.

DOI：10.1016/j.ymthe.2018.05.015

• LEFT-VENTRICULAR FUNCTION
• CHRONIC HEART-FAILURE
• MESENCHYMAL STEM-CELLS
• LIMIT CNS INFLAMMATION
• MONONUCLEAR-CELLS
• ISCHEMIC-HEART
• EXPERIMENTAL STROKE
• RANDOMIZED-TRIAL
• PROGENITOR CELLS
• CLINICAL-TRIAL

Treatment of myocardial infarction (MI) with bone marrow cells (BMCs) improves post-MI cardiac function in rodents. However, clinical trials of BMC therapy have been less effective. While most rodent experiments use young healthy donors, patients undergoing autologous cell therapy are older and post-MI. We previously demonstrated that BMCs from aged and post-MI donor mice are therapeutically impaired, and that donor MI induces inflammatory changes in BMC composition including reduced levels of B lymphocytes. Here, we hypothesized that B cell alterations in bone marrow account for the reduced therapeutic potential of post-MI and aged donor BMCs. Injection of BMCs from increasingly aged donor mice resulted in progressively poorer cardiac function and larger infarct size. Flow cytometry revealed fewer B cells in aged donor bone marrow. Therapeutic efficacy of young healthy donor BMCs was reduced by depletion of B cells. Implantation of intact or lysed B cells improved cardiac function, whereas intact or lysed T cells provided only minor benefit. We conclude that B cells play an important paracrine role in effective BMC therapy for MI. Reduction of bone marrow B cells because of age or MI may partially explain why clinical autologous cell therapy has not matched the success of rodent experiments.

• 出版日期2018-7-5
• 单位河南省人民医院; 郑州大学